文献速递慢性肾脏病肾小球疾病

TRAIL通过死亡受体5诱导糖尿病肾病足细胞PANoptosis

TRAIL induces podocyte PANoptosis via death receptor 5 in diabetic kidney disease.
PubMed 文献 · Kidney Int · 2024-11-19

该研究通过单细胞RNA测序比较3例正常与3例糖尿病肾病患者肾脏样本,发现足细胞中TNFSF10(TRAIL)和TNFRSF10B(DR5)表达显著增加且与病情严重程度相关;体外和体内实验表明TRAIL/DR5自分泌作用通过激活PANoptosis导致足细胞损伤,抑制DR5可减轻糖尿病小鼠白蛋白尿和肾小球损伤。

要点

  • DKD患者足细胞中TRAIL和DR5表达升高,与DKD严重程度相关
  • TRAIL/DR5通过激活PANoptosis诱导足细胞损伤
  • 抑制DR5可减轻糖尿病小鼠白蛋白尿和肾小球损伤

核心结论

  • TRAIL/DR5通过自分泌作用激活PANoptosis诱导糖尿病肾病足细胞损伤。

研究设计与样本

  • 比较3例正常与3例DKD人肾脏样本的单细胞RNA测序数据。
  • 体外培养人足细胞,用TNF-α刺激,通过siRNA沉默或过表达TRAIL/DR5及重组蛋白处理。
  • 体内使用高脂饮食联合链脲佐菌素诱导的肥胖糖尿病小鼠,进行足细胞特异性基因敲除或过表达。
  • 在BTBR ob/ob小鼠中给予可溶性DR5-Fc抑制DR5。

主要发现

  • DKD患者足细胞中TNFSF10和TNFRSF10B表达显著增加,且与DKD严重程度相关。
  • 体外TNF-α刺激人足细胞后TRAIL和DR5表达增加;沉默TRAIL或DR5减轻TNF-α诱导的PANoptosis,而过表达TRAIL、rh-TRAIL或DR5激活剂Bioymifi增强PANoptosis。
  • 足细胞特异性敲除TNFSF10或TNFRSF10B减轻糖尿病小鼠足细胞和肾小球损伤,并减少PANoptosis;足细胞特异性过表达TNFSF10加重白蛋白尿和肾损伤,并增加PANoptosis。
  • DR5抑制剂可溶性DR5-Fc显著减少BTBR ob/ob小鼠的白蛋白尿和肾小球损伤。

临床怎么用

  • TRAIL/DR5轴可能成为糖尿病肾病足细胞保护的新靶点。
  • DR5抑制剂在糖尿病肾病动物模型中显示减少白蛋白尿和肾小球损伤的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Podocytes can undergo PANoptosis (apoptosis, pyroptosis, and necroptosis). Diabetic kidney disease (DKD) is the leading cause of kidney failure, and podocyte loss is a major event leading to the progression of DKD. Here, we compared single cell RNA sequencing (scRNA-seq) data between three normal and three DKD human kidney samples and found a significant increase of TNFSF10 and TNFRSF10B expression in podocytes of patients with DKD. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), coded by TNFSF10, belongs to the TNF superfamily members and TNFRSF10B codes for death receptor 5 (DR5). We confirmed that expression of TRAIL and DR5 increased in podocytes of patients with DKD and correlated with the severity of DKD. In vitro, TNF-α stimulated TRAIL and DR5 expression in cultured human podocytes. Silence of TRAIL or DR5 by small interfering RNA alleviated TNF-α-stimulated podocytes PANoptosis, while overexpression of TRAIL, treatment with recombinant human TRAIL (rh-TRAIL) or the DR5 activator (Bioymifi) enhanced podocytes PANoptosis. In vivo, podocyte-specific deletion of TNFSF10 or TNFRSF10B alleviated podocyte and glomerular injury in high fat diet and streptozotocin-induced obese diabetic mice and was associated with decreased podocyte PANoptosis. Conversely, the induction of TNFSF10 overexpression specifically in podocytes exacerbated albuminuria and kidney injury in diabetic mice with increased podocyte PANoptosis. Additionally, administration of soluble DR5-Fc, an inhibitor of DR5, resulted in a marked reduction in albuminuria and glomerular injury in BTBR ob/ob mice. Our findings suggest a critical autocrine role of TRAIL/DR5 in inducing podocyte injury in DKD via activation of PANoptosis.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Lv Z, Hu J, Su H, et al. TRAIL induces podocyte PANoptosis via death receptor 5 in diabetic kidney disease. Kidney Int. 2024. PMID: 39571905. doi:10.1016/j.kint.2024.10.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。